Antipsychotic drugs in pregnancy: A review of their maternal and fetal effects

Therapeutic Advances in Drug Safety

Volumn 5, Issue 2, 2014, Pages 100-109

  Galbally, Megan ^a   Snellen, Martien ^a   Power, Josephine ^a  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

antipsychotics; bipolar disorder; pregnancy; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

ALCOHOL ABUSE; ANTEPARTUM HEMORRHAGE; BIPOLAR DISORDER; COMORBIDITY; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HIGH BIRTH WEIGHT; HUMAN; LEARNING DISORDER; LOW BIRTH WEIGHT; MAJOR AFFECTIVE DISORDER; NEWBORN PERIOD; NUTRITION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICAL DISEASE; PLACENTAL TRANSFER; POPULATION; PREDICTIVE VALIDITY; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SMALL FOR DATE INFANT; SMOKING; SYSTEMATIC REVIEW; TERATOGENICITY; THIRD TRIMESTER PREGNANCY;

EID: 84898989648     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614522682     Document Type: Review

References (42)

1. Abel K. Howard L. (2014) Schizophrenia, psychopharamacology and pregnancy. In: Galbally M. Snellen M. Lewis A. (eds), Psychopharmacology and Pregnancy – Treatment Efficacy, Risks, and Guidelines. Heidelberg: Springer, in press.
2. Alexander G. Gallagher S. Mascola A. Moloney R. Stafford R. (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20: 177–184.
3. Auerbach J. Hans S. Marcus J. Maeir S. (1992) Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 14: 399–406.
4. Austin M. Kildea S. Sullivan E. (2007) Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust 186: 364–367.
5. Babu G. Desai G. Tippeswamy H. Chandra P. (2010) Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol 30: 331–332.
6. Baldessarini R. Viguera A. (1995) Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 52: 189–192.
7. Bennedsen B. Mortensen P. Olesen A. Henriksen T. (1999) Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. Br J Psychiatry 175: 239–245.
8. Boden R. Lundgren M. Brandt L. Reutfors J. Kieler H. (2012) Antipsychotics During pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry 69: 715–721.
9. Brunner E. Falk D. Dey D. Shatapathy C. (2013) Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 14: 38.
10. Coppola D. Russo L. Kwarta R. Varughese R. Schmider J. (2007) Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Safety 30: 247–264.
11. Czeizel A. Szegal B. Joffe J. Racz J. (1999) The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. Neurotoxicol Teratol 21: 157–167.
12. Einarson A. Boskovic R. (2009) Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 15: 183–192.
13. Finer L. Henshaw S. (2006) Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38: 90–96.
14. Galbally M. Roberts M. Buist A. (2010) Mood stabilizers in pregnancy: a systematic review. Aust N Z J Psychiatry 44: 967–977.
15. Galbally M. Snellen M. Lewis A. (2011) A Review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol 23: 408–414
16. Galbally M. Snellen M. Walker S. Permezel M. (2010) Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 44: 99–108.
17. Gentile S. (2010) Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 36: 518–544.
18. Gilbert P. Harris M. McAdams L. Jeste D. (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52: 173–188.
19. Grof P. Robbins W. Alda M. Berghoefer A. Vojtechovsky M. Nilsson A. (2000) Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 61: 31–39.
20. Habermann F. Frizsche J. Fuhlbruck F. Wacker E. Allignol A. Weber-Schoendorfer C. (2013) Atypical antipsychotic drugs and pregnancy outcome. J Clin Psychopharmacol 33: 453–462.
21. Jablensky A. Morgan V. Zubrick S. Bower C. Yellachich L. (2005) Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 162: 79–91.
22. Johnson K. Laprairie J. Brennan P. Stowe Z. Newport D. (2012) Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 69: 787–794.
23. Lin H. Chen I. Chen Y. Lee H. Wu F. (2010) Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 116: 55–60.
24. McKenna K. Koren G. Tetelbaum M. Wilton L. Shakir S. Diav-Citrin O. (2005) Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66: 444–449; quiz 546.
25. Meador K. Pennell P. Harden C. Gordon J. Tomson T. Kaplan P. (2008) Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 71: 1109–1117.
26. Newham J. Thomas S. Macritchie K. McElhatton P. McAllister-Williams R. (2008) Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 192: 333–337.
27. Newport D. Calamaras M. Devane C. Donovan J. Beach A. Winn S. (2007) Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164: 1214–1220.
28. Niemi L. Suvisaari J. Haukka J. Wrede G. Lonnqvist J. (2004) Cumulative incidence of mental disorders among offspring of mothers with psychotic disorder. Results from the Helsinki High-Risk Study. Br J Psychiatry 185: 11–17.
29. Peng M. Gao K. Ding Y. Ou J. Calabrese J. Wu R. (2013) Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology 228: 577–584.
30. Reis M. Kallen B. (2008) Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 28: 279–288.
31. Slone D. Siskind V. Heinonen O. Monson R. Kaufman D. Shapiro S. (1977) Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 128: 486–488.
32. Snellen M. Mack K. Trauer T. (1999) Schizophrenia, mental state, and mother-infant interaction: examining the relationship. Aust N Z J Psychiatry 33: 902–911.
33. Stephenson C. Karanges E. McGregor I. (2013) Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry 47: 74–87.
34. Stika L. Elisova K. Honzakova L. Hrochova H. Plechatova H. Strnadova J. (1990) Effects of drug administration in pregnancy on children–s school behaviour. Pharm Weekbl Sci 12: 252–255.
35. US Food and Drug Administration (2011) Drug Safety Communication. Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. February 2011. Silver Spring, MD: US Food and Drug Administration.
36. Viguera A. Tondo L. Koukopoulos A. Reginaldi D. Lepri B. Baldessarini R. (2011) Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry 168: 1179–1185.
37. Viguera A. Whitfield T. Baldessarini R. Newport D. Stowe Z. Reminick A. (2007) Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 164: 1817–1824; quiz 1923.
38. Wan M. Green J. (2009) The impact of maternal psychopathology on child-mother attachment. Arch Womens Ment Health 12: 123–134.
39. Wan M. Moulton S. Abel K. (2008) A Review of mother-child relational interventions and their usefulness for mothers with schizophrenia. Arch Womens Ment Health 11: 171–179.
40. Wan M. Salmon M. Riordan D. Appleby L. Webb R. Abel K. (2007) What predicts poor mother-infant interaction in schizophrenia? Psychol Med 37: 537–546.
41. Webb R. Howard L. Abel K. (2004) Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev 2: CD004411.
42. Wichman C. (2009) Atypical antipsychotic use in pregnancy: a retrospective review. Arch Women Ment Health 12: 53–57.